No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Ascendiant Maintains RenovoRx(RNXT.US) With Buy Rating, Raises Target Price to $9
RenovoRx Is Maintained at Buy by Ascendiant Capital
RenovoRx Price Target Raised to $9.00/Share From $8.25 by Ascendiant Capital
RenovoRx Analyst Ratings
RenovoRx Receives First Purchase Orders For Its FDA-Cleared RenovoCath Delivery System
Express News | RenovoRx Receives First Purchase Orders for Its FDA-Cleared Renovocath® Delivery System
Unlock the Full List